索拉非尼对顺铂耐药性舌癌Tca8113/DDP细胞增殖及凋亡影响的体外研究
Effects of sorafenib on the proliferation and apoptosis of cisplatin-resistant tongue cancer cells in vitro

DOI: 10.6040/j.issn.1671-7554.0.2015.566

Keywords: 索拉非尼,舌癌耐药相关蛋白1,舌肿瘤,
Sorafenib,Tongue cancer resistance associated protein 1,Tongue neoplasms

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK Pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66(24): 11851-11858.
[2]	Hsu FT, Chang B, Chiang IT, et al. Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells[J]. In Vivo, 2014, 28(5): 925-934.
[3]	Gu Y, Fan S, Xiong Y, et al. Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line[J]. FEBS Letters, 2011, 585(6): 881-887.
[4]	Peng B, Gu Y, Xiong Y, et al. Microarray-assisted pathway analysis identifies MT1X & NFκB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma[J]. PLoS One, 2012, 7(12): e51413.
[5]	Sharma N, Pennell N, Nickolich M, et al. Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer[J]. Invest New Drugs, 2014, 32(2): 362-368.
[6]	Liu CY, Tseng LM, Su JC, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells[J]. Breast Cancer Res, 2013, 15(4): R63.
[7]	Safarinejad MR. Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study[J]. Urol Oncol, 2010, 28(1): 21-27.
[8]	Massano J, Regateiro FS, Januario G, et al. Oral squamous cell carcinoma: review of prognostic and predictive factors[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2006, 102(1): 67-76.
[9]	Magrath I, Litvak J. Cancer in developing countries: opportunity and challenge[J]. J Natl Cancer Inst, 1993, 85(11): 862-874.
[10]	Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high risk squamous cell carcinoma of the head and neck[J]. N Engl J Med, 2004, 350(19): 1937-1944.
[11]	Simons AL, Mattson DM, Dornfeld K, et al. Glucose deprivation induced metabolic oxidative stress and cancer therapy[J]. J Cancer Res Ther, 2009, 5 Suppl 1: S2-6.
[12]	Zhu H, Liu Z, Tang L, et al. Reversal of P-gp and MRPI-mediated multidrug resistance by H6, a gypenoside aglycon from gynostemma pentaphyllum, in vincristine-resistant human oral cancer(KB/VCR)cells[J]. Eur J Pharmacol, 2012, 696(1-3): 43-53.
[13]	Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer[J]. N Engl J Med, 2004, 350(4): 351-360.
[14]	谷依学, 范莎莎, 王成坤, 等. TCRP1在口腔鳞癌中介导顺铂耐药的体内研究[J]. 中国药理学通报, 2012, 28(11): 1574-1578. GU Yixue, FAN Shasha, WANG Chengkun, et al. TCRP1 mediates the resistance of oral squamous cell carcinoma to cisplatin in vivo[J]. Chinese Pharmacological Bulletin, 2012, 28(11): 1574-1578.
[15]	谷依学, 王成坤, 尹江, 等. TCRP1通过PI3k-Akt途径介导口腔鳞癌顺铂化学治疗耐受[J]. 国际病理科学与临床杂志, 2012, 32(6): 461-468. GU Yixue, WANG Chengkun, YIN Jiang, et al. TCRP1 mediates the resistance of oral squamous cell carcinoma to cisplatin through regulation of PI3K-Akt pathway[J]. Int J Pathol Clin Med, 2012, 32(6): 461-468.
[16]	Kim YB, Jeung HC, Jeong I, et al. Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer[J]. J Radiat Res, 2013, 54(1): 52-60.

Full-Text